Jun 23,2021 11:25 AM
Sun Pharma settles patent litigation Celgene over cancer drug.
Dr Reddys ordered to pay $46.25 mn to Hatchtech Jun 16,2021
|Resolution Type||Description Of Resolution||IiAS Recommendation|
|Name||LTP||PE||Mar Cap||NP Qtr||Div. Yld||Sales Qtr||BV|
|Sun Pharmaceuticals Industries Ltd||664.80||71.55||159,483.80||327.39||1.13||3,119.04||104.36|
|Divis Laboratories Ltd||4,250.35||57.72||112,813.53||487.93||0.47||1,718.39||349.25|
|Dr Reddys Laboratories Ltd||5,277.65||40.16||87,807.45||311.50||0.47||3,313.50||1,020.99|
|Cadila Healthcare Ltd||618.00||38.80||63,236.58||464.70||0.57||1,949.70||124.49|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Dr Reddys Laboratories Ltd (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddys offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilar... More
Reports by dr-reddys-laboratories-ltd-share-price
Jun 25, 2021
Dr. Reddy’s Laboratories (DRL), India’s second-largest pharma company, is expected to see earnings recovery led by cost rationalization and new product approvals; recommendation based on 18x FY21E...More
Jun 25, 2021 03:11 AM
The company’s consolidated revenue stood at Rs3,858cr, up 3.3% yoy but down 4.3% qoq.
14 May 2021
29 Mar 2021
29 Jan 2021
28 Dec 2020
28 Oct 2020
27 Sep 2020